***OPTION 1:***

***THERAPY PROPOSAL***

***MAX 6 pages with times new roman 12, excluding charts.***

***Figures are more than welcome***

***FORMAT***

***Title: MAX 150 characters***

***Abstract: MAX 150 words***

***Keywords: 5 words***

***1-*** ***Importance of the Proposal Subject, Original Value, Research Question or Hypothesis, Objectives***

***• Challenge***

***• Novel Concept and approach***

***• Hypothesis***

***• Objectives***

***2-Methods: Wps: Research methodology and approach* / *Research Design / Tasks& activities***

***Aim I / WP1: Aims should correlate with work packages***

***3-Gantt Chart***

***Example:***

***Minimum three workpackages***

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| WP No | MONTHS | | | | | | | | | | | | | | | | | | | | | | | | |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| WP1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| WP2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| WP3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Deliverable |  |  | 1.1  2.1 |  |  |  |  |  |  |  |  |  | 1.2 |  |  |  |  | 2.2 |  |  |  |  |  | 2.3  3.1 |
| Milestone |  |  |  |  |  |  |  |  |  | 3.1 |  | 1.1  2.1 |  |  |  | 3.2 |  |  |  |  |  |  | 2.2  1.2 |  |

***5-Risk management***

***Example:***

***For each work package at least one risk and a contingency plan***

|  |  |  |  |
| --- | --- | --- | --- |
| **Work Package No** | **Main Risks** | **Risk level** | **Proposed contingency plan** |
| 1 | For genes that are heavily regulated by epigenetic mechanisms, upregulation can occur at minute levels. | Medium | I can replace VP64 with a more effective activator called VPR which contains in p65 and rTA addition to VP64 [16]. |

***OPTION 2:***

***MINI REVIEW FOR A DISEASE CONDITION OR A Therapeutic APPROACH***

***MAX 6 pages with times new roman 12***

***Figures are more than welcome***

***FORMAT***

***Title: MAX 150 characters***

Example: RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies

***Abstract: MAX 150 words***

***Keywords: 5 words***

***1.1.Introduction:***

***1.2.: Disease etiology, therapies and etc.***

***Example***

***1.2. Antisense Oligonucleotides***

***1.3.*** ***Trans-Splicing Molecules***

***1.4.*** ***(s)iRNA and Ribozymes***

***1.5.*** ***U1 Spliceosomal RNA***

***1.6.*** ***Cas13 and ADARs***

***1.7. Perspectives / Future directions:***